keyword
MENU ▼
Read by QxMD icon Read
search

Roger McIntyre

keyword
https://www.readbyqxmd.com/read/28446154/effects-of-escitalopram-and-paroxetine-on-mtorc1-signaling-in-the-rat-hippocampus-under-chronic-restraint-stress
#1
Mi Kyoung Seo, Cheol Min Choi, Roger S McIntyre, Hye Yeon Cho, Chan Hong Lee, Rodrigo B Mansur, Yena Lee, Jae-Hon Lee, Young Hoon Kim, Sung Woo Park, Jung Goo Lee
BACKGROUND: Recent studies have suggested that the activation of mammalian target of rapamycin (mTOR) signaling may be related to antidepressant action. Therefore, the present study evaluated whether antidepressant drugs would exert differential effects on mTOR signaling in the rat hippocampus under conditions of chronic restraint stress. Male Sprague-Dawley rats were subjected to restraint stress for 6 h/days for 21 days with either escitalopram (10 mg/kg) or paroxetine (10 mg/kg) administered after the chronic stress procedure...
April 26, 2017: BMC Neuroscience
https://www.readbyqxmd.com/read/28433459/depressive-disorders-processes-leading-to-neurogeneration-and-potential-novel-treatments
#2
REVIEW
Gregory M Brown, Roger S McIntyre, Joshua Rosenblat, Rüdiger Hardeland
Mood disorders are wide spread with estimates that one in seven of the population are affected at some time in their life (Kessler et al., 2012). Many of those affected with severe depressive disorders have cognitive deficits which may progress to frank neurodegeneration. There are several peripheral markers shown by patients who have cognitive deficits that could represent causative factors and could potentially serve as guides to the prevention or even treatment of neurodegeneration. Circadian rhythm misalignment, immune dysfunction and oxidative stress and circadian rhythm misalignment are key pathologic processes implicated in neurodegeneration and cognitive dysfunction in depressive disorders...
April 19, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28421980/guidelines-for-the-recognition-and-management-of-mixed-depression
#3
Stephen M Stahl, Debbi A Morrissette, Gianni Faedda, Maurizio Fava, Joseph F Goldberg, Paul E Keck, Yena Lee, Gin Malhi, Ciro Marangoni, Susan L McElroy, Michael Ostacher, Joshua D Rosenblat, Eva Solé, Trisha Suppes, Minoru Takeshima, Michael E Thase, Eduard Vieta, Allan Young, Mark Zimmerman, Roger S McIntyre
A significant minority of people presenting with a major depressive episode (MDE) experience co-occurring subsyndromal hypo/manic symptoms. As this presentation may have important prognostic and treatment implications, the DSM-5 codified a new nosological entity, the "mixed features specifier," referring to individuals meeting threshold criteria for an MDE and subthreshold symptoms of (hypo)mania or to individuals with syndromal mania and subthreshold depressive symptoms. The mixed features specifier adds to a growing list of monikers that have been put forward to describe phenotypes characterized by the admixture of depressive and hypomanic symptoms (e...
February 28, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28410777/evidence-for-neurocognitive-improvement-after-bariatric-surgery-a-systematic-review
#4
REVIEW
Gurneet Thiara, Michela Cigliobianco, Alexei Muravsky, Riccardo A Paoli, Rodrigo Mansur, Raed Hawa, Roger S McIntyre, Sanjeev Sockalingam
BACKGROUND: Bariatric surgery is an effective means of weight reduction in severely obese patients and correlates with improvements in quality of life, mental health outcomes, and neurocognition, especially in those with high psychosocial burden. OBJECTIVE: The primary purpose of this systematic review was to evaluate the impact of bariatric surgery on long-term neurocognitive functioning and neuropsychological outcomes. METHODS: OVID Medline and PsychInfo databases from January 1990 to August 2015 were searched with key terms and phrases: "bariatric surgery" and "cognition...
February 21, 2017: Psychosomatics
https://www.readbyqxmd.com/read/28384334/correction-the-association-between-methylphenidate-treatment-and-the-risk-for-fracture-among-young-adhd-patients-a-nationwide-population-based-study-in-taiwan
#5
Vincent Chin-Hung Chen, Yao-Hsu Yang, Yin-To Liao, Ting-Yu Kuo, Hsin-Yi Liang, Kuo-You Huang, Yin-Cheng Huang, Yena Lee, Roger S McIntyre, Tzu-Chin Lin
[This corrects the article DOI: 10.1371/journal.pone.0173762.].
2017: PloS One
https://www.readbyqxmd.com/read/28370311/diagnostic-clusters-associated-with-an-early-onset-schizophrenia-diagnosis-among-children-and-adolescents
#6
Jeanette M Jerrell, Roger S McIntyre, Chelsea B Deroche
OBJECTIVE: Given the greater severity and chronicity of psychiatric disorders that first declare in individuals under the age of 18, early onset schizophrenia (EOS) and its association with co-occurring psychiatric conditions deserve further investigation. METHODS: Cluster and discriminant analyses were used to examine the heterogeneity of children and adolescents diagnosed with schizophrenia in 1 statewide system of care. A retrospective cohort design was employed, using South Carolina's (USA) Medicaid claims dataset covering outpatient and inpatient medical services between January, 1999 and December, 2013 to identify patients ≤17 years of age...
March 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28370310/pharmacotherapy-effectiveness-for-clinical-subgroups-among-children-and-adolescents-with-early-onset-schizophrenia
#7
Jeanette M Jerrell, Roger S McIntyre, Chelsea B Deroche
OBJECTIVE: This study aims to determine the effectiveness of pharmacotherapies among children and adolescents diagnosed with early onset schizophrenia subgrouped according to their co-occurring psychiatric disorders. METHODS: A retrospective cohort design was employed, using South Carolina's (USA) Medicaid claims dataset covering outpatient and inpatient medical services, between January, 1999 and December, 2013 to identify patients ≤17 years of age. Random effects regression analyses assessed differential changes in acute psychiatric service utilization over time across the 3 subgroups associated with antipsychotic, mood stabilizer, psychostimulant, or antidepressant pharmacotherapy...
March 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28350822/asthma-corticosteroid-use-and-schizophrenia-a-nationwide-population-based-study-in-taiwan
#8
Wei-Chen Wang, Mong-Liang Lu, Vincent Chin-Hung Chen, Mei-Hing Ng, Kuo-You Huang, Ming-Hong Hsieh, Meng-Jer Hsieh, Roger S McIntyre, Yena Lee, Charles Tzu-Chi Lee
OBJECTIVE: Asthma and corticosteroid use have been implicated as possible risk factors for schizophrenia. The retrospective cohort study herein aimed to investigate the association between asthma, corticosteroid use, and schizophrenia. METHOD: Longitudinal data (2000 to 2007) from adults with asthma (n = 50,046) and without asthma (n = 50,046) were compared on measures of schizophrenia incidence using Taiwan's National Health Insurance Research Database (NHIRD)...
2017: PloS One
https://www.readbyqxmd.com/read/28338549/reply-to-comments-by-drs-glue-and-menkes
#9
Roger S McIntyre, Yena Lee
No abstract text is available yet for this article.
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28296941/the-association-between-methylphenidate-treatment-and-the-risk-for-fracture-among-young-adhd-patients-a-nationwide-population-based-study-in-taiwan
#10
Vincent Chin-Hung Chen, Yao-Hsu Yang, Yin-To Liao, Ting-Yu Kuo, Hsin-Yi Liang, Kuo-You Huang, Yin-Cheng Huang, Yena Lee, Roger S McIntyre, Tzu-Chin Lin
Attention-deficit hyperactivity disorder (ADHD) is associated with higher risk for fracture. Whether the medical treatment for ADHD would mitigate the risk remains unclear. In this study, we sought to investigate the effect of methylphenidate treatment on risk for fracture, as well the moderational role of treatment duration on the risk of fracture, in a large national sample. Cases less than 18 years old were identified from Taiwan's National Health Insurance Research Database with a new primary diagnosis of ADHD (ICD-9:314) between 1996 and 2013...
2017: PloS One
https://www.readbyqxmd.com/read/28264727/mixed-features-and-mixed-states-in-psychiatry-from-calculus-to-geometry
#11
Roger S McIntyre
No abstract text is available yet for this article.
March 7, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28257449/effects-of-selective-serotonin-reuptake-inhibitors-on-glaucoma-a-nationwide-population-based-study
#12
Vincent Chin-Hung Chen, Mei-Hing Ng, Wei-Che Chiu, Roger S McIntyre, Yena Lee, Tsang-Yaw Lin, Jun-Cheng Weng, Pau-Chung Chen, Chung-Yao Hsu
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are one of the most commonly prescribed classes of antidepressants. Glaucoma is the second leading cause of blindness globally and iatrogenic glaucoma has been implicated across disparate medication classes. Available studies that have sought to determine the association between SSRI exposure and glaucoma have provided mixed results. The aim of the study herein was to investigate whether an association exists between SSRI exposure and glaucoma incidence...
2017: PloS One
https://www.readbyqxmd.com/read/28213943/a-phase-2-safety-study-of-accelerated-elotuzumab-infusion-over-less-than-1-h-in-combination-with-lenalidomide-and-dexamethasone-in-patients-with-multiple-myeloma
#13
James Berenson, Robert Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger Lyons, Wael Harb, Hesham Mohamed, Ali Nourbakhsh, Robert Rifkin
Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-h infusion), combined with lenalidomide and dexamethasone, demonstrated durable efficacy and acceptable safety; 10% (33/321) of patients had infusion reactions (IRs; Grade 1/2: 29; Grade 3: 4). This phase 2 study (NCT02159365) investigated an accelerated infusion schedule in 70 patients with newly diagnosed multiple myeloma or RRMM...
May 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28107669/medical-comorbidity-in-bipolar-disorder-the-link-with-metabolic-inflammatory-systems
#14
REVIEW
Ana SayuriYamagata, Elisa Brietzke, Joshua D Rosenblat, Ron Kakar, Roger S McIntyre
BACKGROUND: Bipolar disorder (BD) is associated with chronic low-grade inflammation, several medical comorbidities and a decreased life expectancy. Metabolic-inflammatory changes have been postulated as one of the main links between BD and medical comorbidity, although there are few studies exploring possible mechanisms underlying this relationship. Therefore, the aims of the current narrative review were 1) synthesize the evidence for metabolic-inflammatory changes that may facilitate the link between medical comorbidity and BD and 2) discuss therapeutic and preventive implications of these pathways...
March 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28078987/role-of-proinflammatory-cytokines-in-dopaminergic-system-disturbances-implications-for-anhedonic-features-of-mdd
#15
Zihang Pan, Joshua D Rosenblat, Walter Swardfager, Roger S McIntyre
Anhedonia, characterized by a loss of interest and/or pleasure in previously enjoyable activities, is an important diagnostic criterion of Major Depressive Disorder (MDD). Converging evidence implicates a behaviouralcausal relationship between proinflammatory cytokines and disturbances that characterize anhedonia in the context of MDD. Additionally, anhedonia has been implicated in disturbances of key central dopaminergic modulatory pathways. Emerging research into the roles of tetrahydrobiopterin, a cytokine-targeted co-enzyme in the synthesis of dopamine, and kynurenine, a product of inflammation-sensitive breakdown of tryptophan via indoleamine 2, 3-dioxygenase, have shed new light into the role of inflammation in mediating anhedonic behaviours...
January 11, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28073041/major-depressive-disorder-with-subthreshold-hypomanic-mixed-features-a-real-world-assessment-of-treatment-patterns-and-economic-burden
#16
Roger S McIntyre, Daisy Ng-Mak, Chien-Chia Chuang, Rachel Halpern, Pankaj A Patel, Krithika Rajagopalan, Antony Loebel
BACKGROUND: To compare outcomes for individuals with major depressive disorder (MDD) with or without subthreshold hypomania (mixed features) in naturalistic settings. METHODS: Using the Optum Research Database (1/1/2009─10/31/2014), a retrospective analysis of individuals newly diagnosed with MDD was conducted. Continuous enrollment for 12-months before and after the initial MDD diagnosis was required. MDD with subthreshold hypomania (mixed features) (MDD-MF) was defined based on ≥1 hypomania diagnosis within 30 days after an MDD diagnosis during the one-year follow-up period, in the absence of bipolar I diagnoses...
March 1, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28068459/does-pharmacogenomic-testing-improve-clinical-outcomes-for-major-depressive-disorder-a-systematic-review-of-clinical-trials-and-cost-effectiveness-studies
#17
Joshua D Rosenblat, Yena Lee, Roger S McIntyre
OBJECTIVE: Pharmacogenomic testing has become scalable and available to the general public. Pharmacogenomics has shown promise for predicting antidepressant response and tolerability in the treatment of major depressive disorder (MDD). In theory, pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. The current systematic review examines the extant literature to determine the impact of pharmacogenomic testing on clinical outcomes in MDD and assesses its cost-effectiveness...
January 3, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28044944/a-pragmatic-approach-to-the-diagnosis-and-treatment-of-mixed-features-in-adults-with-mood-disorders
#18
Roger S McIntyre, Yena Lee, Rodrigo B Mansur
Mixed features specifier (MFS) is a new nosological entity defined and operationalized in the Diagnostic and Statistical Manual of Mental Disorders (DSM), 5th Edition. The impetus to introduce the MFS and supplant mixed states was protean, including the lack of ecological validity, high rates of misdiagnosis, and guideline discordant treatment for mixed states. Mixed features specifier identifies a phenotype in psychiatry with greater illness burden, as evidenced by earlier age at onset, higher episode frequency and chronicity, psychiatric and medical comorbidity, suicidality, and suboptimal response to conventional antidepressants...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28013123/a-randomized-double-blind-placebo-controlled-crossover-trial-evaluating-the-effect-of-intranasal-insulin-on-cognition-and-mood-in-individuals-with-treatment-resistant-major-depressive-disorder
#19
Danielle S Cha, Michael W Best, Christopher R Bowie, Laura Ashley Gallaugher, Hanna O Woldeyohannes, Joanna K Soczynska, Gary Lewis, Glenda MacQueen, Barbara J Sahakian, Sidney H Kennedy, Jane P Lui, Rodrigo B Mansur, Roger S McIntyre
BACKGROUND: Cognitive dysfunction in major depressive disorder (MDD) is identified as a primary therapeutic target; no current treatment is approved for the treatment of cognitive dysfunction in MDD. We examined whether intranasal insulin offered a beneficial effect across measures of cognitive function in adults with MDD. METHODS: Thirty-five adults (18-65 years of age: 47.09±9.89) meeting criteria for a major depressive episode as per the Diagnostic and Statistical Manual (DSM)-IV-Treatment Revised were included in this randomized, double blind, placebo-controlled, crossover design study...
March 1, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/27935809/assessing-and-measuring-cognitive-function-in-major-depressive-disorder
#20
Renee-Marie Ragguett, Danielle S Cha, Ron Kakar, Joshua D Rosenblat, Yena Lee, Roger S McIntyre
Cognitive dysfunction is a major component of major depressive disorder (MDD). No 'gold-standard' tool exists for the assessment of cognitive dysfunction for adults with MDD. The use of measurement-based care to improve treatment outcomes invites the need for a systematic screening, evaluation and measurement tool. The aim herein was to provide a succinct summary of literature documenting clinical implication of cognitive dysfunction in MDD, and a review of available screening, diagnostic and measurement tools for cognitive dysfunction in MDD is provided...
November 2016: Evidence-based Mental Health
keyword
keyword
44509
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"